Edgewise Therapeutics, Inc. (EWTX)
| Market Cap | 3.32B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -167.80M |
| Shares Out | 107.27M |
| EPS (ttm) | -1.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,324,448 |
| Open | 30.94 |
| Previous Close | 30.64 |
| Day's Range | 30.45 - 32.47 |
| 52-Week Range | 12.15 - 35.00 |
| Beta | 0.25 |
| Analysts | Buy |
| Price Target | 39.00 (+25.85%) |
| Earnings Date | May 7, 2026 |
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for EWTX stock is "Buy." The 12-month stock price target is $39.0, which is an increase of 25.85% from the latest price.
News
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutic...
Edgewise Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Key cardiovascular and neuromuscular programs are advancing, with 7500 showing a favorable safety profile and plans for Phase III in HCM by year-end. Becker muscular dystrophy data indicate disease stabilization, and new HFpEF candidates are progressing.
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
–The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies – – Data reinforce prior clinical finding...
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
BOULDER, Colo., March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at t...
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular Dys...
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
– CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 – – Phase 1 healthy adult trial data of EDG-15400 and plans for heart f...
Edgewise Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Major milestones include an upcoming phase III readout for sevasemten in Becker, CIRRUS Part D data in HCM, and phase I initiation for EDG-15400. Enhanced trial designs and strong patient retention support commercial prospects, with phase III HCM trials set for Q4.
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
BOULDER, Colo., Feb. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D.
Edgewise Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Major clinical programs in Becker muscular dystrophy and hypertrophic cardiomyopathy are advancing, with pivotal data readouts and regulatory submissions expected in the next 12–18 months. Strong efficacy, safety, and financial position support commercial launch readiness and expansion into multi-billion dollar markets.
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions - - Presenting at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Janua...
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
BOULDER, Colo., Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D.
Why Did Edgewise Therapeutics Jump 25%+ On Wednesday?
Edgewise Therapeutics (EWTX) surged nearly 26% following the release of favorable interim safety and efficacy data from its Phase 2 CIRRUS-HCM trial for EDG-7500, an oral cardiac sarcomere modulator f...
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
BOULDER, Colo., Dec. 24, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel ora...
Edgewise Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Significant progress was made in both Becker muscular dystrophy and HCM programs, with key biomarker and efficacy endpoints met and improved safety protocols implemented. Phase 3 trials are on track, and eliminating echo monitoring could expand market access.
Edgewise Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Upcoming December data will highlight the 25 mg dose's efficacy and safety in new HCM patient cohorts, with a focus on ejection fraction stability and broader market potential. The 12-week study and pivotal Grand Canyon readout remain on track, while commercial and pipeline preparations advance.
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
BOULDER, Colo. , Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran...
Edgewise Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Strong efficacy and safety data support the drug's differentiation from current therapies, with protocol changes improving patient selection and trial design. Plans include pivotal trials in HCM and HFpEF, regulatory engagement for DMD, and a well-funded path to commercialization.
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
BOULDER, Colo. , Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies an...
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo. , Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the f...
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
– Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch – – MESA open-label extension trial of sevasemte...
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society
BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th Internation...
Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
– Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies – – Announce...
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $EWTX--EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
Edgewise Therapeutics Transcript: Study Result
Sevasemten showed sustained disease stabilization and favorable safety in Becker and Duchenne muscular dystrophy, with pivotal Grand CANYON phase III fully enrolled and top-line data expected in late 2026. FDA feedback supports the approval path, and the company is well-funded for upcoming milestones.